Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Pfizer
Pfizer
AstraZeneca
National Institutes of Health Clinical Center (CC)
University of Southern California
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
Hummingbird Bioscience
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.
Shanghai Jiao Tong University School of Medicine
Canadian Cancer Trials Group
Seagen Inc.
Roswell Park Cancer Institute
Eli Lilly and Company
Novartis
Bayer
Bristol-Myers Squibb
Eli Lilly and Company
Gilead Sciences
Incyte Corporation
Celgene
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Dana-Farber Cancer Institute
Hoffmann-La Roche
EMD Serono
Sanofi
Altor BioScience
NewVac LLC
Washington University School of Medicine
Merck Sharp & Dohme LLC
Radiation Therapy Oncology Group
Debiopharm International SA
Amgen
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)